Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Operating Leases: 2022-2025

Historic Operating Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $48.0 million.

  • Entrada Therapeutics' Operating Leases fell 10.31% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 10.31%. This contributed to the annual value of $51.6 million for FY2024, which is 14.38% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Operating Leases of $48.0 million as of Q3 2025, which was down 2.50% from $49.3 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Operating Leases high stood at $73.0 million for Q2 2023, and its period low was $16.2 million during Q1 2023.
  • For the 3-year period, Entrada Therapeutics' Operating Leases averaged around $53.2 million, with its median value being $53.6 million (2024).
  • Per our database at Business Quant, Entrada Therapeutics' Operating Leases slumped by 49.07% in 2023 and then surged by 258.28% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Operating Leases (Quarterly) stood at $17.5 million in 2022, then skyrocketed by 244.10% to $60.3 million in 2023, then dropped by 14.38% to $51.6 million in 2024, then decreased by 10.31% to $48.0 million in 2025.
  • Its last three reported values are $48.0 million in Q3 2025, $49.3 million for Q2 2025, and $50.5 million during Q1 2025.